Nearly $800 Million “Woke” Grants Roar Back

NIH website displayed on a computer screen

(DailyChive.com) – A massive court-forced reversal is pushing NIH to reopen the spigot on frozen DEI and gender-identity grants, putting nearly a billion dollars in contested “woke” research back on the table.

Story Snapshot

NIH must reconsider thousands of DEI and gender-identity grants worth roughly $783 million under court-approved settlements.
Trump-era directives had stalled or killed more than 5,000 grants touching DEI, LGBTQ+ health, vaccine hesitancy, and similar themes.
Federal judges found the mass terminations likely unlawful, forcing NIH to restore over 2,000 awards and restart reviews.
NIH is stripping DEI requirements from future grants, even as courts force a one-time reconsideration of past applications.

How Trump’s NIH Crackdown Put DEI Research on Defense

Early in 2025, the returning Trump administration moved quickly to stop using taxpayer dollars to bankroll sprawling DEI and gender-ideology agendas inside federal health research. Senior officials at Health and Human Services and the National Institutes of Health issued internal guidance telling staff to deprioritize or prohibit grants that centered on DEI, gender identity, and related ideological projects. That guidance led NIH to terminate hundreds of existing awards and freeze new proposals in categories elite bureaucrats had previously treated as untouchable.

The affected grants ranged widely, from transgender health and LGBTQ+ initiatives to environmental health, workforce diversity schemes, vaccine hesitancy studies, and COVID-19 projects that often carried a heavy political overlay. Universities, teaching hospitals, and advocacy groups that had grown reliant on Washington dollars for these priorities suddenly found their pipelines shut off. For many conservative taxpayers frustrated with years of identity politics in medicine and public health, the shift looked like long-overdue oversight of mission creep inside NIH.

Lawsuits, Court Orders, and a Forced Retreat on Frozen Grants

The crackdown did not go unchallenged. Individual scientists, professional associations, labor unions, and a coalition of Democratic state attorneys general rushed to federal court in Massachusetts, accusing NIH and the administration of unlawful, politically motivated grant cancellations. They argued that once an award is made, agencies cannot rip it back without solid legal reasoning and proper process under the Administrative Procedure Act. Judges focused heavily on the fact that NIH invoked DEI labels it never clearly defined while yanking funding midstream.

By June 2025, U.S. District Judge William Young ruled that NIH likely broke the law and ordered more than 2,000 terminated grants restored. The First Circuit Court of Appeals later described internal guidance that flatly barred NIH from funding certain DEI and gender-identity categories at all. The Supreme Court stepped in as well, acknowledging serious problems with the anti-DEI directives but limiting how much direct monetary relief grantees could receive, and sending many funding claims to the Court of Federal Claims rather than rewriting executive-branch budgets from the bench.

The $783 Million Reconsideration Deal and What It Really Means

Under mounting legal pressure, NIH and the Trump administration agreed to settlements in late December 2025 that force a full reconsideration of stalled applications. The agency must now re-review thousands of frozen, denied, or withdrawn grants using its normal scientific process and “good faith” standards, without applying the earlier anti-DEI filter. A Supreme Court analysis in the related litigation estimated that roughly $783 million in funding had been caught up in the dispute, underscoring the enormous scale of the prior DEI-era portfolio.

These settlements set strict deadlines. Non-competing renewals had to be decided by the date of filing. New awards that had already gone through peer review and advisory council scrutiny must receive funding decisions by January 12, 2026. Other applications face mid-April or late-July 2026 decision points, depending on where they sit in the review pipeline. Inside Higher Ed and other outlets report NIH is already approving “droves” of applications, with hundreds of once-shelved grants now moving forward under the court-ordered framework.

Trump’s Broader Course Correction: Ending DEI Requirements Going Forward

While courts are forcing NIH to reconsider old grants, the administration is simultaneously reshaping the rules for future funding in ways that matter to constitutional conservatives. NIH has started removing formal DEI components from its opportunities, including diversity plans and “Plans for Enhancing Diverse Perspectives,” and has stated that any such plans already submitted will no longer affect funding decisions. Policy language on inclusion is being narrowed to focus on women and racial or ethnic minority groups, without the sweeping equity rhetoric that previously dominated.

NIH Director Jay Bhattacharya has made the long-term direction plain. He has said publicly that although some DEI-related grants must be temporarily restored or reconsidered because of the court orders, those projects “will not be renewed” when they come up again in 2026 if they no longer match NIH priorities. That stance signals a clear break from years of bureaucratic enthusiasm for social-justice framing in science. For readers worried about runaway government promoting divisive identity politics, this represents a significant strategic realignment of federal research power.

At the same time, the settlements reveal how deeply entrenched DEI funding became before the course correction began. More than 5,000 grants nationwide are covered in the agreements with state attorneys general alone, and Massachusetts officials say NIH had to issue decisions on 528 of those grants the very day the settlement was filed. Advocacy groups frame this as a victory for “urgent public health” work on issues such as HIV prevention, sexual violence, and LGBTQ+ health. Taxpayers focused on core biomedical research may see it as proof of how far the agenda had drifted.

What Conservative Readers Should Watch Next

For conservative Americans who value limited government, constitutional checks, and a clear line between hard science and ideology, this saga underscores both opportunity and risk. On one hand, Trump’s team has used executive authority to pull back from institutionalized DEI inside NIH and signal that identity-focused projects are no longer default priorities. On the other hand, litigation has shown how fast well-organized interest groups and blue-state officials can use the courts to shield favored funding streams, even when voters elect a different agenda.

Looking ahead, the key questions are whether Congress will reinforce this pivot with more explicit limits on ideological grant-making, and whether NIH leadership will consistently apply merit-based criteria instead of quietly rebuilding DEI under new labels. The reconsideration of nearly a billion dollars in disputed grants is a reminder that budgets are moral documents: every dollar steered back toward real medical breakthroughs is a dollar not spent advancing woke social experiments under the banner of “public health.” Vigilant oversight will determine which path prevails.